UnknownPhase 3

Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency

China10 participantsStarted 2021-10-11

Plain-language summary

Emergency treatment warning of clevidipine butyrate butyrate injection or invalid medical treatment and verification of the effectiveness and safety of subacute.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18 years old ≤ age ≤ 75 years old, men and women are not restricted;
✓. Hypertensive emergency and hypertensive sub-emergency patients who are not suitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective and require intravenous medication to quickly control blood pressure, and meet one of the following conditions: ① Consultation systolic blood pressure (SBP)\> Patients with 180mmHg and/or consulting room diastolic blood pressure (DBP)\> 120mmHg, with or without target organ damage;
✓. To participate in this clinical trial voluntarily, the subject (or legal representative) signs an informed consent form.

Exclusion criteria

✕. Those who cannot receive intravenous infusion of antihypertensive drugs for 18 hours or more;
✕. Patients with severe lipid metabolism abnormalities (such as triglycerides\> 5mmol/L, familial hypercholesterolemia, lipid nephropathy, or acute pancreatitis accompanied by hyperlipidemia);
✕. Patients who are known to have severe liver insufficiency or a history of liver failure or cirrhosis;
✕. Patients who are known to be intolerant or allergic to study drugs or calcium channel blockers, or are allergic to the ingredients of study drug excipients, or are allergic to soybeans, soy products, eggs and egg products;
✕. Patients with known or suspected severe aortic stenosis;
✕. Those with a clear history of secondary hypertension (including: pheochromocytoma, primary aldosteronism, etc.);
✕. Patients with known or suspected aortic dissection;
✕. Those with a history of drug or alcohol abuse, and those with acute hypertension caused by drug overdose;

What they're measuring

The percentage of patients whose systolic blood pressure dropped to the target range within 30 minutes of starting the infusion.

Timeframe: 30 minutes

Trial details

NCT IDNCT05044364

SponsorShenzhen People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-01

Contact for this trial

JIN XIAOHUI, 34

18645005162 517026400@163.com

View on ClinicalTrials.gov More Hypertensive Emergency trials